Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.

ABSTRACT:

Importance

Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-generation sequencing provide a route to therapeutic approaches, and integrating DNA and RNA analysis with clinicopathologic data may be a crucial step toward personalized treatment strategies for this disease.

Objective

To classify PDAC according to distinct mutational processes, and explore their clinical significance.

Design, setting, and participants

We performed a retrospective cohort study of resected PDAC, using cases collected between 2008 and 2015 as part of the International Cancer Genome Consortium. The discovery cohort comprised 160 PDAC cases from 154 patients (148 primary; 12 metastases) that underwent tumor enrichment prior to whole-genome and RNA

SUBMITTER: Connor AA 

PROVIDER: S-EPMC5824324 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature